Itch

American Kidney Fund Brings Kidney Health Education to All During Fourth Annual Virtual Kidney Action Week on March 20-24

Retrieved on: 
Monday, March 20, 2023
Steps, Medicine, Kidney failure, Diabetes, American Kidney Fund, Kidney disease, American Heart Association, AKF, Health care, Weight gain, Life, Hypertension, Risk, Transplant, Dialysis, Restless legs syndrome, Homelessness Action Week, Congress, Patient, Grief, Diabetic nephropathy, Itch, Kidney, Knowledge, Eli Lilly and Company, Chronic kidney disease, Exercise, Therapy, Mandy Sellars, CKD, Skin, Tanning (leather), Dietary supplement, Pharmaceutical industry, Communications satellite, Dentistry

Kidney Action Week occurs as AKF continues to recognize Kidney Month , a time of unity and action on behalf of all those affected by kidney disease.

Key Points: 
  • Kidney Action Week occurs as AKF continues to recognize Kidney Month , a time of unity and action on behalf of all those affected by kidney disease.
  • Approximately 37 million Americans have kidney disease and 9 out of 10 people with early-stage kidney disease are unaware they have it.
  • Kidney Action Week will cover topics such as healthy eating, medical treatments for kidney disease, living donor transplantation, dialysis and mental well-being.
  • Kidney Action Week is part of AKF’s Know Your Kidneys™ kidney disease education and prevention program.

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Retrieved on: 
Saturday, March 18, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Maintenance, Psoriasis Area and Severity Index, EASI, Week, Dermatology, American Academy, Atopic dermatitis, IGA, 2008 Giro d'Italia, Stage 1 to Stage 11, Patient, Itch, AD, Skin, Inflammation, Vaccine

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.

Key Points: 
  • Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.
  • In the study “CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002),” researchers reported on results from Stage 1 of the pivotal China trial of CBP-201 in moderate-to-severe AD.
  • Patients on active therapy experienced rapid relief of symptoms, with a reduction in itch at Week 1 and significant improvement in all study endpoints by Week 4, which was sustained to Week 16.
  • “We are honored to have data from our two CBP-201 atopic dermatitis studies at the prestigious American Academy of Dermatology Annual Meeting, showing rapid and sustained relief,” said Zheng Wei, Ph.D., Co-founder and CEO of Connect Biopharma.

AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant Impact on Prurigo Nodularis

Retrieved on: 
Saturday, March 18, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Pharmacokinetics, American Academy, Associate, Prurigo, Skin, Patient, AAD, Itch, American Academy of Dermatology, Prurigo nodularis, Nemolizumab, III, Safety, Johns Hopkins School of Medicine, Pharmaceutical industry, Dermatology

Galderma has an extensive presence at the meeting with further updates from its broad portfolio across Therapeutic Dermatology, Dermatological Skincare and Injectable Aesthetics.

Key Points: 
  • Galderma has an extensive presence at the meeting with further updates from its broad portfolio across Therapeutic Dermatology, Dermatological Skincare and Injectable Aesthetics.
  • The phase III OLYMPIA 2 trial met all primary endpoints, showing nemolizumab monotherapy significantly improved pruritus (itch) and skin lesions compared with placebo in adult patients with moderate to severe prurigo nodularis.
  • “We are so pleased that we’re able to bring so much powerful new data to this year’s AAD congress.
  • Its continued commitment to delivering science and innovation across a highly differentiated portfolio is reflected in its extensive presence at AAD.

Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

Retrieved on: 
Saturday, March 18, 2023
American Academy of Dermatology, Oregon Health and Science University Center for Women's Health, Clinical trial, Quality of life, American Academy, Atopic dermatitis, Regeneron Pharmaceuticals, Patient, AAD, Annual general meeting, Itch, Human, Skin, Vaccine, Pharmaceutical industry, Dupilumab, Sanofi

TARRYTOWN, N.Y. and PARIS, March 18, 2023 (GLOBE NEWSWIRE) --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis. The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints. The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting.

Key Points: 
  • The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints.
  • The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting.
  • There were significant improvements in measures of hand and foot skin pain, sleep, and hand eczema-related quality of life.
  • The trial demonstrated similar safety results to the known safety profile of Dupixent in atopic dermatitis.

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Retrieved on: 
Saturday, March 18, 2023
Human, Clinical trial, Itch, Quality of life, American Academy of Dermatology, American Academy, Atopic dermatitis, Patient, AAD, Skin, Annual general meeting, Vaccine, Dupilumab

Positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis were presented today.

Key Points: 
  • Positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis were presented today.
  • The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints.
  • “Atopic hand and foot dermatitis can extensively disrupt the lives of patients, given the intense itch and painful skin lesions it causes on essential body areas.
  • There were significant improvements in measures of hand and foot skin pain, sleep and hand eczema-related quality of life.

Kyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis at the American Academy of Dermatology Annual Meeting 2023

Retrieved on: 
Friday, March 17, 2023
NRS, Pros, Inflammation, Dermatology Life Quality Index, Week, Chills, Sleep, Fever, American Academy, Atopic dermatitis, Common, MSAD, Pain, Kyowa Kirin, OX40, DLQI, Patient, AAD, Pain scale, Itch, American Academy of Dermatology, Annual general meeting, Nausea, Aphthous stomatitis, Immunoglobulin E, Headache, SD, TSE, Disease, Vaccine, Aluminium, Copper, Silviculture

AD affects 15-20% of children and up to 10% of adults, making it the 15th most common nonfatal disease.

Key Points: 
  • AD affects 15-20% of children and up to 10% of adults, making it the 15th most common nonfatal disease.
  • "We are pleased to share this additional data from the rocatinlimab Phase 2b study," said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin.
  • From baseline to Week 16, percentage reductions in NRS-pruritus (p≤0.029) and NRS-SD scores (p≤0.025) were greater in the rocatinlimab groups compared with placebo.
  • The most frequent TEAEs, reported in ≥ 10% of subjects in the combined rocatinlimab groups were nasopharyngitis, worsening of AD, pyrexia and chills.

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

Retrieved on: 
Thursday, March 16, 2023
The Retreat, SPR, SPRINT, Quality of life, Therapy, MD, Trial of the century, Patient, Interventional pain management, Itch, Pain, Central nervous system, PNS, Clinical trial, Doctor of Philosophy, SIS, Chronic pain, Pharmaceutical industry, Nursing, Research

“Some of this study’s most important findings are the continued durability and impacts beyond the 60-day SPRINT® PNS treatment period.

Key Points: 
  • “Some of this study’s most important findings are the continued durability and impacts beyond the 60-day SPRINT® PNS treatment period.
  • In addition, 58 percent of participants had clinically meaningful improvement in two or more outcomes at 14 months.
  • 75 percent of participants who reported taking opioids at baseline reported reductions in opioid consumption in the months after PNS.
  • The most common adverse events were mild skin irritation or pruritis at the bandage or stimulator’s mounting pad.

Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

Retrieved on: 
Wednesday, March 15, 2023
Linda, 2020 Henry Ford Health System 200, Adolescence, Pediatrics, Quality of life, Atopic dermatitis, Itch, Psoriasis, BSA, Clinical research, Dermatitis, Body surface area, Roivant Sciences, Patient, Rady, Physician, FDA, Pharmacist, Diagnosis, Prescription, JD, Week, Plaque, Surveying, Pharmaceutical industry, Cosmetics, Dietary supplement, EASI, MD, Dermatology

“Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

Key Points: 
  • “Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.
  • In the U.S., VTAMA cream is already approved for the topical treatment of plaque psoriasis in adults.
  • Importantly, VTAMA cream data indicated no safety or tolerability signals in this population including children as young as 2 years old.
  • “Atopic dermatitis can have a negative impact on the quality of life of diagnosed children as well as their families.

Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report

Retrieved on: 
Tuesday, March 14, 2023
Therapy, Workforce, Itch, Biophysical environment, Cara, Female, Patient, Carbon footprint, Workplace, Social responsibility, ESG, Community, Plastic, Policy, Pharmaceutical industry, Management

STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today released its inaugural Environmental, Social, and Governance (ESG) report highlighting the Company’s efforts in key areas such as corporate governance, diversity and inclusion in the workplace, environmental stewardship and social responsibility.

Key Points: 
  • STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today released its inaugural Environmental, Social, and Governance (ESG) report highlighting the Company’s efforts in key areas such as corporate governance, diversity and inclusion in the workplace, environmental stewardship and social responsibility.
  • “Our first ESG report establishes a solid reporting baseline of the work underway at Cara Therapeutics that extends beyond our commitment to transforming the way chronic pruritus is treated and reflects our focus on innovating sustainability, operating responsibly and empowering people,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics.
  • Highlights of the report include:
    Corporate governance: The Company has implemented a cross-functional ESG Group that will meet on a regular basis and report to the Board of Directors periodically on policy implementation and improvement.
  • Workplace diversity: The Company continues to strengthen its diversity and inclusivity efforts including a gender-balanced leadership team and Board of Directors.

Hims & Hers Announces New Anti-Dandruff Shampoo for Hims Customers

Retrieved on: 
Wednesday, March 15, 2023
Online Retail, Retail, Health, Consumer, Specialty, General Health, Men, Foam, Hims & Hers Health, Multimedia, Hers, Drop, Itch, NYSE, Life, Hair loss, Finasteride, CVS, Inflammation, Dandruff, Zinc, Argania, Paraben, Scalp, Conditioner, Sulfate, Homs, Cosmetics, Petroleum jelly, Amazon

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, is today announcing Hims Dandruff Detox, a unique shampoo formulated with doctors that both fights dandruff and supports scalp health.

Key Points: 
  • Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, is today announcing Hims Dandruff Detox, a unique shampoo formulated with doctors that both fights dandruff and supports scalp health.
  • This powerful and gently-cleansing formula was developed with doctors to be vegan, cruelty-free and free of parabens, phthalates, sulfates and dyes.
  • View the full release here: https://www.businesswire.com/news/home/20230315005632/en/
    Hims Dandruff Detox - Hims & Hers Health, Inc. (Photo: Business Wire)
    “Our Hims & Hers customers continue to demand more products that address hair health right at the source.
  • “We set out to create an effective dandruff shampoo that helps to remove flakes, itch and scalp irritation.